Literature DB >> 32471843

Down Syndrome Disintegrative Disorder: A Clinical Regression Syndrome of Increasing Importance.

Mattia Rosso1, Ellen Fremion2, Stephanie L Santoro3,4, Nicolas M Oreskovic5, Tanuja Chitnis1, Brian G Skotko5,4, Jonathan D Santoro6,7.   

Abstract

Down syndrome disintegrative disorder (DSDD), a developmental regression in children with Down syndrome (DS), is a clinical entity that is characterized by a loss of previously acquired adaptive, cognitive, and social functioning in persons with DS usually in adolescence to early adulthood. Initially reported in 1946 as "catatonic psychosis," there has been an increasing interest among the DS community, primary care, and subspecialty providers in this clinical area over the past decade. This condition has a subacute onset and can include symptoms of mood lability, decreased participation in activities of daily living, new-onset insomnia, social withdrawal, autistic-like regression, mutism, and catatonia. The acute phase is followed by a chronic phase in which baseline functioning may not return. No strict criteria or definitive testing is currently available to diagnose DSDD, although a comprehensive psychosocial and medical evaluation is warranted for individuals presenting with such symptoms. The etiology of DSDD is unknown, but in several hypotheses for regression in this population, psychological stress, primary psychiatric disease, and autoimmunity are proposed as potential causes of DSDD. Both psychiatric therapy and immunotherapies have been described as DSDD treatments, with both revealing potential benefit in limited cohorts. In this article, we review the current data regarding clinical phenotypes, differential diagnosis, neurodiagnostic workup, and potential therapeutic options for this unique, most disturbing, and infrequently reported disorder.
Copyright © 2020 by the American Academy of Pediatrics.

Entities:  

Year:  2020        PMID: 32471843     DOI: 10.1542/peds.2019-2939

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  8 in total

1.  Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder.

Authors:  Jonathan D Santoro; Rebecca Partridge; Runi Tanna; Dania Pagarkar; Mellad Khoshnood; Mustafa Rehmani; Ryan M Kammeyer; Grace Y Gombolay; Kristen Fisher; Allison Conravey; Jane El-Dahr; Alison L Christy; Lina Patel; Melanie A Manning; Heather Van Mater; Michael S Rafii; Eileen A Quinn
Journal:  J Neurodev Disord       Date:  2022-06-03       Impact factor: 4.074

2.  Case Report: Improvement Following Immunotherapy in an Individual With Seronegative Down Syndrome Disintegrative Disorder.

Authors:  Sarah J Hart; Gordon Worley; Priya S Kishnani; Heather Van Mater
Journal:  Front Neurol       Date:  2021-03-26       Impact factor: 4.003

3.  Acute Regression in Down Syndrome.

Authors:  Benjamin Handen; Isabel Clare; Charles Laymon; Melissa Petersen; Shahid Zaman; Sid O'Bryant; Davneet Minhas; Dana Tudorascu; Stephanie Brown; Bradley Christian
Journal:  Brain Sci       Date:  2021-08-23

4.  Abnormal Weight Loss in an Adolescent Female With Down Syndrome.

Authors:  Monica Garcia; Florentina Litra
Journal:  Cureus       Date:  2022-07-13

5.  Assessment and Diagnosis of Down Syndrome Regression Disorder: International Expert Consensus.

Authors:  Jonathan D Santoro; Lina Patel; Ryan Kammeyer; Robyn A Filipink; Grace Y Gombolay; Kathleen M Cardinale; Diego Real de Asua; Shahid Zaman; Stephanie L Santoro; Sammer M Marzouk; Mellad Khoshnood; Benjamin N Vogel; Runi Tanna; Dania Pagarkar; Sofia Dhanani; Maria Del Carmen Ortega; Rebecca Partridge; Maria A Stanley; Jessica S Sanders; Alison Christy; Elise M Sannar; Ruth Brown; Andrew A McCormick; Heather Van Mater; Cathy Franklin; Gordon Worley; Eileen A Quinn; George T Capone; Brian Chicoine; Brian G Skotko; Michael S Rafii
Journal:  Front Neurol       Date:  2022-07-15       Impact factor: 4.086

Review 6.  A Systematic Review of Unexplained Early Regression in Adolescents and Adults with Down Syndrome.

Authors:  Madeleine Walpert; Shahid Zaman; Anthony Holland
Journal:  Brain Sci       Date:  2021-09-10

7.  Personalized medicine for rare neurogenetic disorders: can we make it happen?

Authors:  Agnies M van Eeghen; Hilgo Bruining; Nicole I Wolf; Arthur A Bergen; Riekelt H Houtkooper; Mieke M van Haelst; Clara D van Karnebeek
Journal:  Cold Spring Harb Mol Case Stud       Date:  2022-03-24

8.  Opportunities, barriers, and recommendations in down syndrome research.

Authors:  James A Hendrix; Angelika Amon; Leonard Abbeduto; Stamatis Agiovlasitis; Tarek Alsaied; Heather A Anderson; Lisa J Bain; Nicole Baumer; Anita Bhattacharyya; Dusan Bogunovic; Kelly N Botteron; George Capone; Priya Chandan; Isabelle Chase; Brian Chicoine; Cécile Cieuta-Walti; Lara R DeRuisseau; Sophie Durand; Anna Esbensen; Juan Fortea; Sandra Giménez; Ann-Charlotte Granholm; Laura J Hahn; Elizabeth Head; Hampus Hillerstrom; Lisa M Jacola; Matthew P Janicki; Joan M Jasien; Angela R Kamer; Raymond D Kent; Bernard Khor; Jeanne B Lawrence; Catherine Lemonnier; Amy Feldman Lewanda; William Mobley; Paul E Moore; Linda Pollak Nelson; Nicolas M Oreskovic; Ricardo S Osorio; David Patterson; Sonja A Rasmussen; Roger H Reeves; Nancy Roizen; Stephanie Santoro; Stephanie L Sherman; Nasreen Talib; Ignacio E Tapia; Kyle M Walsh; Steven F Warren; A Nicole White; Guang William Wong; John S Yi
Journal:  Transl Sci Rare Dis       Date:  2021-04-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.